Investor Presentaiton

INVESTOR 20 DAY 23 GUARDANTREVEAL The only tissue-free MRD test available clinically Currently in CRC, breast and lung ✅ Upgrade to Smart Liquid Biopsy this year $20B+ U.S. market in early development 15M+ Patients <3% Patients tested today GUARDANT™ 1 ACS Cancer Treatment & Survivorship Facts & Figures 2019-2021 2 Guardant assessment based on tissue availability post diagnosis. The ACS Cancer Treatment & SurvivorshipFacts & Figures 2019-2021 states 1/3 of the 15M cancer survivors were diagnosed in the last 5 years. Tissue availability significantly decreases over time. 60

View entire presentation